These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32201138)

  • 1. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan.
    Qamar FN; Yousafzai MT; Khaliq A; Karim S; Memon H; Junejo A; Baig I; Rahman N; Bhurgry S; Afroz H; Sami U
    Vaccine; 2020 Apr; 38(19):3518-3523. PubMed ID: 32201138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
    Yousafzai MT; Karim S; Qureshi S; Kazi M; Memon H; Junejo A; Khawaja Z; Ur Rehman N; Ansari MS; Ali R; Ujjan IU; Lohana HM; Memon NM; Hussain M; Nigar R; Bar-Zeev N; Qamar FN
    Lancet Glob Health; 2021 Aug; 9(8):e1154-e1162. PubMed ID: 34297962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
    Longley AT; Date K; Luby SP; Bhatnagar P; Bentsi-Enchill AD; Goyal V; Shimpi R; Katkar A; Yewale V; Jayaprasad N; Horng L; Kunwar A; Harvey P; Haldar P; Dutta S; Gidudu JF
    Clin Infect Dis; 2021 Aug; 73(4):e927-e933. PubMed ID: 33502453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
    Thobani RS; Yousafzai MT; Sultana S; Kazi AM; Jan M; Rafey A; Khan A; Irfan S; Ujjan IU; Brown N; Mårtensson A; Qamar FN
    Vaccine; 2022 Aug; 40(36):5391-5398. PubMed ID: 35945044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
    Batool R; Yousafzai MT; Qureshi S; Muhammad S; Qazi I; Sadaf T; Ashorn P; Qamar FN
    Vaccine; 2023 Aug; 41(37):5376-5382. PubMed ID: 37463829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine.
    Yousafzai MT; Qamar FN; Shakoor S; Saleem K; Lohana H; Karim S; Hotwani A; Qureshi S; Masood N; Rauf M; Khanzada JA; Kazi M; Hasan R
    Clin Infect Dis; 2019 Feb; 68(Suppl 1):S16-S21. PubMed ID: 30767003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to Improve Coverage of Typhoid Conjugate Vaccine (TCV) Immunization Campaign in Karachi, Pakistan.
    Qamar FN; Batool R; Qureshi S; Ali M; Sadaf T; Mehmood J; Iqbal K; Sultan A; Duff N; Yousafzai MT
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33228111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
    Batool R; Tahir Yousafzai M; Qureshi S; Ali M; Sadaf T; Mehmood J; Ashorn P; Naz Qamar F
    Vaccine; 2021 Sep; 39(40):5858-5865. PubMed ID: 34465474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coverage survey of typhoid conjugate vaccine among children aged 6 months to 15 years in an urban slum settlement of Lyari Town Karachi, Pakistan.
    Batool R; Qureshi S; Haq Z; Yousafzai MT; Salam RA; Ali R; Sadaf T; Ali M; Qamar FN
    PLoS One; 2023; 18(8):e0289582. PubMed ID: 37549155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
    N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-centre, post-marketing surveillance study of Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®) in India.
    Reddy R; Reddy B; Sarangi V; Reddy S; Ella R; Vadrevu KM
    Hum Vaccin Immunother; 2022 Dec; 18(1):1947761. PubMed ID: 34242128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
    Date K; Shimpi R; Luby S; N R; Haldar P; Katkar A; Wannemuehler K; Mogasale V; Pallas S; Song D; Kunwar A; Loharikar A; Yewale V; Ahmed D; Horng L; Wilhelm E; Bahl S; Harvey P; Dutta S; Bhatnagar P
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S172-S178. PubMed ID: 32725235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge, attitudes, and practices of the general population of Pakistan regarding typhoid conjugate vaccine: findings of a cross-sectional study.
    Tahir MJ; Zaman M; Saffi J; Asghar MS; Tariq W; Ahmed F; Islam R; Farooqui US; Ullah I; Saqlain M; Ullah K; Ahmed A
    Front Public Health; 2023; 11():1151936. PubMed ID: 37333546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
    Nampota-Nkomba N; Nyirenda OM; Khonde L; Mapemba V; Mbewe M; Ndaferankhande JM; Msuku H; Masesa C; Misiri T; Mwakiseghile F; Patel PD; Patel P; Johnson-Mayo I; Pasetti MF; Heyderman RS; Tracy JK; Datta S; Liang Y; Neuzil KM; Gordon MA; Laurens MB;
    Lancet Glob Health; 2022 Sep; 10(9):e1326-e1335. PubMed ID: 35961356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.